Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry

Poorhoseini, Hamid Reza; Kassaian, Seyed Ebrahim; Hoseini, Kianoosh; Saroukhani, Sepideh; Salarifar, Mojtaba; Alidoosti, Mohammad; Nematipour, Ebrahim; Haji-Zeinali, Ali Mohammad; Amirzadegan, Alireza; Mohammadzadeh, Mir Hossein Seyyed; Vatan, K Khadem; Aghajani, Hassan; Fathollahi, Mahmood Sheikh; Farrokh‐Eslamlou, Hamidreza

doi:10.1177/1753944716629868

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demographic, clinical, angiographic and follow-up data of the eligible patients were retrieved from the THC databank, which its characteristics has been described elsewhere 11, 12. Cardiovascular risk factors were also reviewed for each patient, including diabetes mellitus, hypertension, dyslipidemia, smoking, opium abuse, and family history of coronary artery disease as defined institutionally based on the international guidelines 13 .…”

Section: Methdosmentioning

confidence: 99%

Predictors of major adverse cardiac events following elective stenting of large coronary arteries

Aghajani

Alkamel

Shafiee

et al. 2018

Indian Heart Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methdosmentioning

confidence: 99%

Predictors of major adverse cardiac events following elective stenting of large coronary arteries

Aghajani

Alkamel

Shafiee

et al. 2018

Indian Heart Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials

Bundhun

Yanamala

Huang

2017

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundTwo thousand fifteen has been a winning year for Drug Eluting Stents (DES). Increase in the number of patients with cardiovascular diseases treated by Percutaneous Coronary Intervention (PCI) has resulted to a high demand for second generation DES. This current analysis aimed to compare the different types of Stent Thrombosis (ST) associated with Zotarolimus Eluting Stents (ZES) versus Everolimus Eluting Stents (EES) at 1 year follow up.MethodsElectronic databases were searched for studies comparing ZES with EES. Different types of ST reported at 1 year follow up were considered as the primary endpoints in this analysis. Odds Ratios (OR) with 95% Confidence Intervals (CIs) were used as the statistical parameters and the pooled analyses were carried out by the RevMan 5 · 3 software.ResultsA total number of 10,512 patients were included in this analysis. No significant difference in any definite ST, acute definite ST, subacute definite ST, and late definite ST were observed between ZES and EES, at 1 year follow up with OR: 1.70, 95% CI: 0.92 – 3.16; P = 0.09, OR: 3.44, 95% CI: 0.82 – 14.43; P = 0.09, OR: 1.13, 95% CI: 0.43 – 2.95; P = 0.80 and OR: 2.39, 95% CI: 0.83 – 6.85; P = 0.11 respectively. Moreover, any definite or probable ST and definite/probable/possible ST were also not significantly different with OR: 1.39, 95% CI: 0.89 – 2.17; P = 0.15 and OR: 1.19, 95% CI: 0.84 – 1.70; P = 0.33 respectively. In addition, any probable ST, acute probable ST, late probable ST and possible ST were also not significantly different at 1 year follow up with OR: 1.11, 95% CI: 0.60 – 2.05; P = 0.75, OR: 0.53, 95% CI: 0.12 – 2.40; P = 0.41, OR: 1.67, 95% CI: 0.35 – 7.86; P = 0.52 and OR: 1.08, 95% CI: 0.64 – 1.82; P = 0.78 respectively.ConclusionAt 1 year follow up, ZES were not associated with significantly lower or higher definite and probable ST compared to EES. In addition, no significant difference was observed in acute, subacute and late definite or probable ST. However, further trials are recommended to assess the effects of these second-generation DES during the long-term.

show abstract

Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry

Abstract: According to our results, it could be concluded that the difference in the rate of MACE between the ZES and EES groups was not statistically significant at 12-month follow up.

Cited by 2 publications

References 31 publications

Predictors of major adverse cardiac events following elective stenting of large coronary arteries

Predictors of major adverse cardiac events following elective stenting of large coronary arteries

Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials

Contact Info

Product

Resources

About